BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32247650)

  • 1. Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India.
    Ganguly S; Pushpam D; Mian A; Chopra A; Gupta R; Bakhshi S
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e437-e444. PubMed ID: 32247650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India.
    Phukan A; Mandal PK; Dolai TK
    Ann Hematol; 2021 Jan; 100(1):85-96. PubMed ID: 33025163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
    Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
    [No Abstract]   [Full Text] [Related]  

  • 6. Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
    Molica M; Colafigli G; Scalzulli E; Alunni Fegatelli D; Chiatamone Ranieri S; Rizzo L; Diverio D; Efficace F; Latagliata R; Foà R; Breccia M
    Ann Hematol; 2019 Aug; 98(8):1891-1904. PubMed ID: 31079264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Study of Clinical Profile and Long Term Outcome to Imatinib Mesylate Alone in Childhood Chronic Myeloid Leukemia in Chronic Phase.
    Department of Medical and Pediatric Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat. INDIA
    Gulf J Oncolog; 2017 Jan; 1(23):15-20. PubMed ID: 28271997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
    Bourlon C; Hernandez-Mata C; Vargas-Serafín C; Bourlon MT; Tuna-Aguilar E; Aguayo A
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):453-9. PubMed ID: 27259590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
    Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
    Pan P; Wang L; Wang Y; Shen L; Zheng P; Bi C; Zhang A; Lv Y; Xue Z; Sun M; Sun C; Li J; Jin L; Yao Y
    Acta Haematol; 2020; 143(3):204-216. PubMed ID: 31514197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
    Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
    Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of Chronic Myeloid Leukemia-Chronic Phase Patients Treated With Imatinib: A Local Experience.
    Al-Amri AM
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):199-203. PubMed ID: 29397347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
    Pan Y; Wen S; Tian J; Lyu Z; Du Z; Yan L
    Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):194-7. PubMed ID: 26165016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
    Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
    J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicenter retrospective clinical study].
    Jiang H; Zhi LT; Hou M; Wang JX; Wu DP; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):566-571. PubMed ID: 28810322
    [No Abstract]   [Full Text] [Related]  

  • 18. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
    Jabbour E; Kantarjian HM; O'Brien S; Shan J; Quintás-Cardama A; Garcia-Manero G; Rios MB; Cortes JE
    J Clin Oncol; 2011 Nov; 29(32):4260-5. PubMed ID: 21990394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
    Suttorp M; Schulze P; Glauche I; Göhring G; von Neuhoff N; Metzler M; Sedlacek P; de Bont ESJM; Balduzzi A; Lausen B; Aleinikova O; Sufliarska S; Henze G; Strauss G; Eggert A; Kremens B; Groll AH; Berthold F; Klein C; Groß-Wieltsch U; Sykora KW; Borkhardt A; Kulozik AE; Schrappe M; Nowasz C; Krumbholz M; Tauer JT; Claviez A; Harbott J; Kreipe HH; Schlegelberger B; Thiede C
    Leukemia; 2018 Jul; 32(7):1657-1669. PubMed ID: 29925908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.